BIOMAT Database Logo BIOMAT Database Logo

Infection at the time of peripheral blood stem cell leukapheresis results in reduced granulocyte-macrophage colony forming unit yields. 1995

P R Johnson, and C L Fitzsimmons, and J Chang, and G R Morgenstern, and J H Scarffe

UI MeSH Term Description Entries
D007937 Leukapheresis The preparation of leukocyte concentrates with the return of red cells and leukocyte-poor plasma to the donor. Leukocytapheresis,Leukopheresis,Lymphapheresis,Lymphocytapheresis,Leukocytopheresis,Lymphocytopheresis,Lymphopheresis,Leukaphereses,Leukocytaphereses,Leukocytophereses,Leukophereses,Lymphaphereses,Lymphocytaphereses,Lymphocytophereses,Lymphophereses
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D009894 Opportunistic Infections An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression. Infection, Opportunistic,Infections, Opportunistic,Opportunistic Infection
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016179 Granulocyte Colony-Stimulating Factor A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines. Colony-Stimulating Factor, Granulocyte,G-CSF,Myeloid Growth Factor,Colony Stimulating Factor, Granulocyte,Factor, Granulocyte Colony-Stimulating,Factor, Myeloid Growth,Granulocyte Colony Stimulating Factor,Growth Factor, Myeloid
D018380 Hematopoietic Stem Cell Transplantation Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms. Stem Cell Transplantation, Hematopoietic,Transplantation, Hematopoietic Stem Cell

Related Publications

P R Johnson, and C L Fitzsimmons, and J Chang, and G R Morgenstern, and J H Scarffe
Large volume leukapheresis following peripheral blood stem cell mobilization by cyclophosphamide and granulocyte-macrophage colony stimulating factor.
January 1994, Progress in clinical and biological research,
P R Johnson, and C L Fitzsimmons, and J Chang, and G R Morgenstern, and J H Scarffe
Prediction of engraftment after autologous peripheral blood progenitor cell transplantation: CD34, colony-forming unit-granulocyte-macrophage, or both?
May 2007, Transfusion,
P R Johnson, and C L Fitzsimmons, and J Chang, and G R Morgenstern, and J H Scarffe
Blood stem cell collection: factors influencing the recovery of granulocyte-macrophage colony forming cells.
January 1996, Cell transplantation,
P R Johnson, and C L Fitzsimmons, and J Chang, and G R Morgenstern, and J H Scarffe
Interleukin-10 inhibits spontaneous colony-forming unit-granulocyte-macrophage growth from human peripheral blood mononuclear cells by suppression of endogenous granulocyte-macrophage colony-stimulating factor release.
February 1997, Blood,
P R Johnson, and C L Fitzsimmons, and J Chang, and G R Morgenstern, and J H Scarffe
Increase in circulating colony-forming units-granulocyte-macrophage during large-volume leukapheresis: evaluation of a new cell separator.
May 1991, Transfusion,
P R Johnson, and C L Fitzsimmons, and J Chang, and G R Morgenstern, and J H Scarffe
Effect of chemotherapy on colony-forming unit-granulocyte macrophage from bone marrow and peripheral blood in patients with lung cancer.
January 1992, Oncology,
P R Johnson, and C L Fitzsimmons, and J Chang, and G R Morgenstern, and J H Scarffe
Comparison between granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the mobilization of peripheral blood stem cells.
May 2002, Current opinion in hematology,
P R Johnson, and C L Fitzsimmons, and J Chang, and G R Morgenstern, and J H Scarffe
The effect of mast cell growth factor on peripheral blood granulocyte-macrophage colony-forming cells in methylcellulose in myeloproliferative disorders.
October 1995, European journal of haematology,
P R Johnson, and C L Fitzsimmons, and J Chang, and G R Morgenstern, and J H Scarffe
Prolonged thrombocytopenia after administration of granulocyte colony-stimulating factor and leukapheresis in a donor for allogeneic peripheral blood stem cell transplantation.
August 1996, Bone marrow transplantation,
P R Johnson, and C L Fitzsimmons, and J Chang, and G R Morgenstern, and J H Scarffe
Production of macrophage-, granulocyte-, granulocyte-macrophage- and multi-colony-stimulating factor by peripheral blood cells.
March 1989, European journal of immunology,
Copied contents to your clipboard!